• 1
    Schroder FH, Van Der Maas P, Beemsterboer P et al. Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study for Prostate Cancer. J Natl Cancer Inst 1998; 90: 181723
  • 2
    Issa MM, Zasada W, Ward K et al. The value of digital rectal examination as a predictor of prostate cancer diagnosis among United States Veterans referred for prostate biopsy. Cancer Detect Prev 2006; 30: 26975
  • 3
    Richie JP, Catalona WJ, Ahmann FR et al. Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal examination. Urology 1993; 42: 36574
  • 4
    Thompson IM, Ankerst DP, Chi C et al. Assessing prostate cancer risk: results from the prostate cancer prevention trial. J Nat Cancer Inst 2006; 98: 52934
  • 5
    Canby-Hagino E, Hernandez J, Brand TC et al. Prostate cancer risk with positive family history, normal prostate examination findings, and PSA less than 4.0 ng/ml. Urology 2007; 70: 74852
  • 6
    National Cancer Institute. Available at: Accessed 25 July 2008
  • 7
    Nadler RB, Humphrey PA, Smith DS et al. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol 1995; 154: 40713
  • 8
    Sindhwani P, Wilson CM. Prostatitis and serum prostate-specific antigen. Curr Urol Rep 2005; 6: 30712
  • 9
    Bhanot S, Gopalakrishnan R, Oliver RT. Post-biopsy rise in serum PSA. A potential tool for the dynamic evaluation of prostate cancer/prostatic intraepithelial neoplasia (PIN). Cancer Biol Ther 2003; 2: 6770
  • 10
    Kiran PR. Markedly raised serum prostate specific antigen levels. Prostatic infarction rather than malignancy? Aust Fam Physician 2001; 30: 45860
  • 11
    Oremek GM, Seiffert UB. Physical activity releases prostate-specific antigen (PSA) form the prostate gland into blood and increases serum PSA concentrations. Clin Chem 1996; 42: 6915
  • 12
    Banez LL, Hamilton RJ, Partin AW et al. Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA 2007; 298: 227580
  • 13
    Fall K, Garmo H, Andren O et al. Prostate specific antigen level as a predictor of lethal prostate cancer. J Natl Cancer Inst 2007; 99: 52632
  • 14
    Zappa M, Ciatto S, Bonardi R et al. Overdiagnosis of prostate carcinoma by screening: an estimate based on the results of the Florence Screening Pilot Study. Ann Oncol 1998; 9: 1297300
  • 15
    Bussemakers MJG, Van Bokhoven A, Verhaegh GW et al. DD3: a new prostate-specific gene, highly over-expressed in prostate cancer. Cancer Res 1999; 59: 59759
  • 16
    Hessels D, Klein Gunnewiek MT, Van Oort I et al. DD3PCA3-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003; 44: 816
  • 17
    Haese A, De La Taille A, Van Poppel H et al. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol 2008 Epub ahead of print
  • 18
    Sokoll L, Ellis W, Lange P et al. A multicenter evaluation of the PCA3 molecular urine test: preanalytical effects, analytical performance, and diagnostic accuracy. Clin Chim Acta 2008; 389: 16
  • 19
    Marks LS, Fradet Y, Deras IL et al. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 2007; 69: 5325
  • 20
    Van Gils MP, Hessels D, Van Hooij O et al. The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance. Clin Cancer Res 2007; 13: 93943
  • 21
    Deras IL, Aubin SMJ, Blase A et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol 2008; 179: 158792
  • 22
    Groskopf J, Aubin SM, Deras IL et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem 2006; 52: 108995
  • 23
    Nakanishi H, Groskopf J, Fritsche HA et al. PCA3 molecular urine assay correlates with prostate cancer tumour volume: implication in selecting candidates for active surveillance. J Urol 2008; 179: 180410
  • 24
    Parekh DJ, Ankerst DP, Groskopf J et al. Predicting prostate cancer risk through incorporation of a molecular biomarker, PCA3. AUA Annual Meeting, 2008
  • 25
    Welch GH, Schwartz LM, Woloshin S. Prostate-specific antigen levels in the United States. Implications of various definitions for abnormal. JNCI 2005; 97: 11327